SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that it has filed a international patent application under the Patent Cooperation Treaty (PCT) entitled, Extracorporeal Removal of Microvesicular Particles. Microvesicular particles are secreted by tumor cells and are known to depress the immune response in cancer patients. They shield tumor cells from the immune response by inducing T-cell apoptosis and blocking T-cell signaling, proliferation, cytokine production, and cytotoxicity. The patent application augments Aethlon’s intellectual property portfolio, and is associated with early stage research initiatives to evolve the mechanisms of the Aethlon Hemopurifier® to be a potential method to assist in the treatment of cancer. Aethlon’s primary focus is to commercialize the Hemopurifier as the first-in-class device to treat a broad-spectrum of infectious disease conditions. The Patent Cooperation Treaty (PCT) is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in 137 member nations. A patent application filed under the PCT is called an international application or PCT application
